199 related articles for article (PubMed ID: 27341131)
1. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Cuapio A; Post M; Cerny-Reiterer S; Gleixner KV; Stefanzl G; Basilio J; Herndlhofer S; Sperr WR; Brons NH; Casanova E; Zimmer J; Valent P; Hofer E
Oncotarget; 2016 Jul; 7(29):46466-46481. PubMed ID: 27341131
[TBL] [Abstract][Full Text] [Related]
2. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
3. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
5. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
[TBL] [Abstract][Full Text] [Related]
6. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
[TBL] [Abstract][Full Text] [Related]
7. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
8. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
9. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.
Frey M; Packianathan NB; Fehniger TA; Ross ME; Wang WC; Stewart CC; Caligiuri MA; Evans SS
J Immunol; 1998 Jul; 161(1):400-8. PubMed ID: 9647249
[TBL] [Abstract][Full Text] [Related]
10. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
[TBL] [Abstract][Full Text] [Related]
11. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
12. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
13. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species.
Romero AI; Thorén FB; Brune M; Hellstrand K
Br J Haematol; 2006 Jan; 132(1):91-8. PubMed ID: 16371024
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells.
Kusumi M; Yamashita T; Fujii T; Nagamatsu T; Kozuma S; Taketani Y
J Reprod Immunol; 2006 Jun; 70(1-2):33-42. PubMed ID: 16488482
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
16. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
17. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
18. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.
Campos C; López N; Pera A; Gordillo JJ; Hassouneh F; Tarazona R; Solana R
Biogerontology; 2015 Oct; 16(5):671-83. PubMed ID: 25991472
[TBL] [Abstract][Full Text] [Related]
19. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
Wagner JA; Rosario M; Romee R; Berrien-Elliott MM; Schneider SE; Leong JW; Sullivan RP; Jewell BA; Becker-Hapak M; Schappe T; Abdel-Latif S; Ireland AR; Jaishankar D; King JA; Vij R; Clement D; Goodridge J; Malmberg KJ; Wong HC; Fehniger TA
J Clin Invest; 2017 Nov; 127(11):4042-4058. PubMed ID: 28972539
[TBL] [Abstract][Full Text] [Related]
20. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells.
Morandi F; Ferretti E; Castriconi R; Dondero A; Petretto A; Bottino C; Pistoia V
Blood; 2011 Nov; 118(22):5840-50. PubMed ID: 21989990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
